Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia. J Pharm Pract 2019 Oct 23:897190019882866

Date

10/28/2019

Pubmed ID

31645190

DOI

10.1177/0897190019882866

Scopus ID

2-s2.0-85074444502

Abstract

BACKGROUND: Argatroban and bivalirudin are direct thrombin inhibitors (DTIs) used for the treatment of heparin-induced thrombocytopenia (HIT). The purpose of this study was to determine whether either agent offered an advantage in efficacy and ability to remain within the targeted therapeutic anticoagulation range.

METHODS: This was a single-center, retrospective, observational cohort study at a large academic medical center. The primary efficacy outcome was time to therapeutic anticoagulation, defined as total number of hours to achieve 2 consecutive activated partial thromboplastin time (aPTT) values in goal range.

RESULTS: A total of 91 patients were included in the analysis. Average time to initial therapeutic anticoagulation was 4.71 hours and 9.8 hours for the argatroban and bivalirudin groups, respectively ( < .01).

CONCLUSIONS: Argatroban may be advantageous compared to bivalirudin in achieving initial therapeutic anticoagulation goals among patients with suspected or confirmed HIT.

Author List

Duewell BE, Briski MJ, Feih JT, Rinka JRG, Tawil JN

Author

Justin N. Tawil MD Assistant Professor in the Anesthesiology department at Medical College of Wisconsin




jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473